Active substance |
Asfotase alfa |
Holder |
Alexion Pharma |
Status |
Running |
Indication |
long-term enzyme replacement therapy in patients with - hypophosphatasia (HPP) in whom the first symptoms presented before the age of 18, to treat the bone manifestations of the disease |
Public documents |
|
Last update |
10/07/2023 |
Strensiq®
Last updated on 13/02/2024